Antisense oligonucleotide inhibition of hepatitis C virus genotype 4 replication in HepG2 cells

Cancer Cell International

Volumn 6, Issue , 2006, Pages

  El Awady, Mostafa K ^a   El Din, Noha G Badr ^a   El Garf, Wael T ^a   Youssef, Samar S ^a   Omran, Moataza H ^a   El Abd, Jasmin ^a   Goueli, Said A ^b,c  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTISENSE PHOSPHOROTHIOIC ACID OLIGONUCLEOTIDE; COMPLEMENTARY DNA; DNA FRAGMENT; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; POLYPROTEIN; UNCLASSIFIED DRUG; VIRUS RNA;

5' UNTRANSLATED REGION; ANTIVIRAL ACTIVITY; ARTICLE; CELL ADHESION; CELL BASED GENE THERAPY; CELL CULTURE; CELL FREE SYSTEM; CELL STRAIN HEPG2; CONTROLLED STUDY; EGYPT; GENE CONSTRUCT; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC TRANSFECTION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NONHUMAN; QUANTITATIVE ANALYSIS; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSLATION; SEQUENCE ANALYSIS; TRANSLATION INITIATION; VIRUS GENOME; VIRUS INHIBITION; VIRUS LOAD;

EID: 33746659538     PISSN: 14752867     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-6-18     Document Type: Article

References (38)

1. Hoofingale JH: Hepatitis C-the clinical spectrum of disease. Hepatology 1997, 26:S15-S20.
2. Willems M, Metselaar HJ, Tilanus HW, Schelm SW, deMan RA: Liver transplantation and hepatitis C. Transplant Int 2002, 15:61-72.
3. Scott LJ, Perry CM: Interferon a2b plus ribavirin- a review of its use in the treatment of chronic hepatitis C. Drugs 2002, 62:507-556.
4. Tan S-L, Pause A, Shi Y, Sonenberg N: Hepatitis C therapeutics: current status and emerging strategies. Nature Rev Drug Discovery 2002, 1:867-881.
5. Manns MP, et al.: PEG-interferon-α2b plus ribavirin compared with interferon- α 2b plus ribavirin for initial treatment of chronic hepatitis: a randomized trial. Lancet 2001, 358:958-965.
6. Crooke ST: Progress in antisense technology. Ann Rev Med 2004, 55:61-95.
7. Dasgupta A, Das S, Izumi R, Venkatesan A, Barat B: Targeting internal ribosome entry site (IRES)-mediated translation to block hepatitis C and other RNA viruses. FEMS Microbiology Letters 2004, 234:189-199.
8. Alt M, Renz R, Hofschneider PH, Paumgartner G, Caselmann WHO: Specific inhibition of hepatitis C viral gene expression by antisense phosphorothionate oligonucleotides. Hepatology 1995, 22:707-717.
9. Bartenschlager R: In vitro models for hepatitis C. Viral Research 2002, 82:25-32.
10. El-Awady MK, Abdel Rahman MM, Ismail SM, Amr KS, Gad YZ, Omran M, Mohamed SA: Prediction of relapse after interferon therapy in HCV infection by use of triple assay. Journal of Gastroenterology and Hepatology in press.
11. Hanecak R. Brown-Driver V, Maureen CF, et al.: Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. Hepatology 1996, 70:5203-5212.
12. Ohno O, Mizokami M, Wu RR, et al.: New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997, 35:201-7.
13. Fong TL, Shindo M, Feinstone SM, Hoofnagle JH, Di Bisceglie AM: Detection of replicative intermediate of hepatitis C viral RNA in liver and serum of patients with chronic hepatitis C. J Clin Invest 1991, 88:1058-60.
14. Martell M, Gomez J, Esteban JI, et al.: High throughput real-time reverse transcription-PCR quantitation of Hepatitis C virus RNA. J Clin Microbiology 1999, 37:327-332.
15. Imanishi T, Obika S: Down-regulation of a gene expression by an antisense BNA oligonucleotide. Nippon Yakurigaku Zasshi 2002, 120:85-90.
16. McHutchison JG, Patel K: Future therapy of Hepatitis C. Hepotology 2002, 36(Suppl):245-252.
17. Cornberg M, Wedemeyer H, Manns MP: Hepatitis C: Therapeutic perspectives. Forum (Genova) 2001, 11:154-62.
18. Heintges T, Encke J, zu Putlitz J, Wands JR: Inhibition of hepatitis C virus NS3 function by antisense oligodeoxynucleotides and protease inhibitor. J Med Virol 2001, 64:671-680.
19. Stefanie Seipp, Muller HM, Pfaff E, Stremmel W, Theilmann L, Goeser T: Establishment of persistent hepatitis C virus infection and replication in vitro. J Gen Virol 1997, 78:2467-2476.
20. Dash S, Halim A, Tsuji H, Hiramatsu N, Gerber MA: Transfection of HepG2 cells with infectious hepatitis C virus genome. Am J Pathology 1997, 151:363-373.
21. Takehara T, Hayashi N, Miaymoto Y, Yamamoto M, Mita E, Fusamoto H, Kamada T: Expression of the hepatitis C virus genome in rat liver after cationic liposome-mediated in vivo gene transfer. Hepatology 1995, 21:746-751.
22. Ito T, Yasui K, Mukaigawa J, Katsume A, Kohara M, Mitamura K: Acquisition of susceptibility to hepatitis C virus replication in HepG2 cells by fusion with primary human hepatocytes: establishment of a quantitative assay for hepatitis C virus infectivity in a cell culture system. Hepatology 2001, 34:566-72.
23. de Diesbach P, Berens C, N'Kuli F: Identification, purification and partial characterization of an oligonucleotide receptor in membranes of HepG2 cells. Nucleic Acid Research 2000, 28:868-874.
24. Wu CH, Wu GY: Targeted inhibition of hepatitis C virus-directed gene expression in human hepatoma cell lines. Gastroenterology 1998, 11:1304-1312.
25. Bacaniello VR, Baltimore D: Cloned poliovirus complementary DNA is infectious in mammalian cells. Science 1981, 214:916-919.
26. Bergmann M, Garcia-Sastre A, Palese P: Transfection mediated recombination of Influenza A virus. J Virology 1992, 66:7576-780.
27. Schuster C, Isel C, Imbert I, Ehresmann C, Marquet R, Kieny MP: Secondary structure of the 3′ terminus of hepatitis C virus minus-strand RNA. J Virology 2002, 76:8058-68.
28. Smith RM, Walton CM, Wu CH, Wu GY: Secondary structure and hybridization accessibility of hepatitis C virus 3′-terminal sequences. J Virology 2002, 76:9563-74.
29. McCaffrey AP, Ohashi K, Meuse L, et al.: Determinants of hepatitis C translational initiation in vitro, in cultured cells and mice. Mol Ther 2002, 5:676-84.
30. Ito T, Lai MMC: Determination of the secondary structure of and cellular protein binding to the 3′-untranslated region of the hepatitis C virus RNA genome. J Virology 1997, 71:8698-706.
31. Tsuchihara K, Tanaka T, Hijikata M, et al.: Specific interaction of polypyrimidine tract-binding protein with the extreme 3′-terminal structure of the hepatitis C virus genome, the 3′X. J Virology 1997, 71:6720-26.
32. Brown EA, Zhang H, Ping LH, Lemon SM: Secondary structure of the 5′ non-translated regions of hepatitis C virus and pestivirus genomic RNAs. Nucleic Acids Res 1992, 20:5041-45.
33. Jubin R, Vantuno NE, Kieft JS, et al.: Hepatitis C virus Internal ribosome entry site (IRES) stem loop IIId contains a phylogenetically conserved GGG triplet essential for translation and IRES folding. J Virology 2000, 74:10430-37.
34. Radhakrishnan SK, Layden TJ, Gartel AL: RNA interference as a new strategy against viral hepatitis. Virology 2004, 323:173-181.
35. Randall G, Grakoui A, Rice CM: Clearance of replicating hepatitis C virus replicon RNA in cell culture by small interfering RNAs. Proc Natl Acad Sci USA 2003, 100:235-240.
36. Paroo Z, Corey DR: Challenges for RNAi in vivo. Trends in Biotechnology 2004, 22:390-394.
37. Moulton HM, Nelson MH, Hatlevig SA, Reddy MT, Iversen PL: Cellular Uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug Chem 2004, 15:290-299.
38. Kelemen BR, Hsiao K, Goueli SA: Selective in vivo inhibition of mitogen-activated protein kinase activation using cell-permeable peptides. J Biol Chem 2002, 277:8741-8748.